Pain Treatment Articles & Analysis
123 news found
Introduction Recent marketing efforts by loupe manufacturers have claimed to offer the “only clinically proven ergonomic loupe”. This assertion focuses on the benefits of refractive loupes with deflection prism, positioning them as the exclusive solution for chronic neck and back pain in dental professionals.5 However, while refractive loupes can improve posture by using refractive ...
As the pharmaceutical industry advances, oral thin films are emerging as innovative solutions across various therapeutic areas. From cardiovascular treatments to pain management, OTF systems are playing a significant role in the future of drug delivery. ...
(Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced a new partnership with Perigon Pharmacy 360, a full-service, specialty digital pharmacy, to enhance accessibility, affordability and adherence for patients treating symptoms of ADHD with Tris’ ...
(Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that Health Canada has authorized the use of Quillivant® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12. ...
Cebranopadol is the first and only dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist (dual-NMR) analgesic in clinical development for the treatment of moderate to severe pain, as well as opioid use disorder (OUD). ...
It has been clinically proven by medical units at home and abroad that its performance is stable and its efficacy is precise and safe, enabling patients to get rid of "pathological blemishes" without pain or marks. Safety of Q-switched Nd:YAG laser treatment The Q-switched Nd:YAG laser is very safe for the treatment of cosmetic dermatoses and has ...
In addition, picosecond laser treatment of blemishes is less difficult to perform and the recovery period after treatment is relatively short. ...
(Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced the appointments of Thomas Englese as chief commercial officer and Marc Lesnick, Ph.D., as chief development officer. ...
The former is suitable for superficial pigmentation such as freckles and sun spots; the latter is suitable for the treatment of deep-seated spots such as brownish nevus, nevus of Ota, melasma, etc. ...
Patent provides protection for High Frequency Spinal Cord Stimulation with Beat Technology Vancouver, Washington – March 20, 2015 – Meagan Medical Inc., a clinical research and medical device development company focused on investigating and developing optimal ways of managing and controlling pain, announced today the issuance of a key patent related to a unique ...
Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain. Multiple clinical studies have demonstrated that cebranopadol is efficacious in different types of pain. ...
” About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster ...
(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare, LLC (Joerns) within selected managed care health systems. ...
Afshin Divani, Associate Professor Neurology at the University of New Mexico commented, “We are pleased to have successfully completed this study of nVNS as a possible treatment for TBI and believe our data suggest that nVNS could be a feasible treatment for TBI/concussion. ...
Bexson’s lead therapy, BB106, is a low-dose ketamine treatment for post-operative pain management, a $36B global market and leading driver of opioid addiction. ...
Hacker at Grossmont Orthopaedic Medical Group is the only physician in San Diego County – and the center is one of just 10 sites nationwide – participating in the SUN clinical trial to evaluate the investigational NUsurface Meniscus Implant (pronounced “new surface”) for the treatment of persistent knee pain caused by injured or ...
Active Implants, LLC, a company that develops orthopedic implant solutions, today announced enrollment of the 100th patient in clinical trials evaluating the NUsurface® Meniscus Implant for the treatment of persistent knee pain caused by injured or deteriorating meniscus tissue. ...
Over the past 90 days, the Company has been focused on the optimization of its Rotigotine TDS formulation for the treatment of Parkinson’s disease, with multiple novel but related formulas under development. ...
The most accurate depth, deep effect, ideal effect. 5. The treatment time is short, about 50 minutes. 6. No anesthesia, no pain, no damage, and the treatment process is more comfortable. 7. ...
Classification of fractional lasers From the perspective of treatment methods, fractional laser is divided into two types: peeling and no peeling. ...